223

PDHX Antibody | 22-212

(No reviews yet) Write a Review
SKU:
223-22-212-GEN
NULL541.00

Description

PDHX Antibody | 22-212 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-300 of human PDHX (NP_003468.2) .

Research Area: Cancer, Signal Transduction

Tested Application: WB, IF

Application: WB: 1:500 - 1:2000
IF: 1:10 - 1:100

Specificiy: N/A

Positive Control 1: SW620

Positive Control 2: HepG2

Positive Control 3: U-251MG

Positive Control 4: MCF7

Positive Control 5: Mouse heart

Positive Control 6: Mouse testis

Molecular Weight: Observed: 54kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: PDHX, E3BP, OPDX, PDX1, proX, DLDBP, pyruvate dehydrogenase complex, component X, E3-binding protein, lipoyl-containing component X

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The pyruvate dehydrogenase (PDH) complex is located in the mitochondrial matrix and catalyzes the conversion of pyruvate to acetyl coenzyme A. The PDH complex thereby links glycolysis to Krebs cycle. The PDH complex contains three catalytic subunits, E1, E2, and E3, two regulatory subunits, E1 kinase and E1 phosphatase, and a non-catalytic subunit, E3 binding protein (E3BP) . This gene encodes the E3 binding protein subunit; also known as component X of the pyruvate dehydrogenase complex. This protein tethers E3 dimers to the E2 core of the PDH complex. Defects in this gene are a cause of pyruvate dehydrogenase deficiency which results in neurological dysfunction and lactic acidosis in infancy and early childhood. This protein is also a minor antigen for antimitochondrial antibodies. These autoantibodies are present in nearly 95% of patients with the autoimmune liver disease primary biliary cirrhosis (PBC) . In PBC, activated T lymphocytes attack and destroy epithelial cells in the bile duct where this protein is abnormally distributed and overexpressed. PBC eventually leads to cirrhosis and liver failure. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

View AllClose

Additional Information

Size:
50 uL
View AllClose